Surrozen, Inc.
SRZN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001824893
In the last 90 days, Surrozen, Inc. insiders filed 0 open-market purchases and 1 sale; 70 institutions reported holding it in 13F filings for Q2 2026, worth $314.5M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Surrozen, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- 0 vs. Q4 2023
- Shares held
- 957.3K
- −34.8K (−3.5%) vs. Q4 2023
- Total value
- $15.0M
- +$5.67M (+60.7%) vs. Q4 2023
- New holders
- 1
- 4 more added
- Sold out
- 1
- 4 more reduced
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SRZN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 70 | $314.5M |
| Q1 2026 | 59 | $314.2M |
| Q4 2025 | 55 | $195.1M |
| Q3 2025 | 36 | $81.7M |
| Q2 2025 | 31 | $53.9M |
| Q1 2025 | 30 | $63.5M |
| Q4 2024 | 24 | $35.4M |
| Q3 2024 | 23 | $25.5M |
| Q2 2024 | 21 | $23.1M |
| Q1 2024 | 16 | $15.0M |
| Q4 2023 | 17 | $9.78M |
| Q3 2023 | 25 | $7.90M |
| Q2 2023 | 22 | $8.62M |
| Q1 2023 | 23 | $9.91M |
| Q4 2022 | 26 | $9.36M |
| Q3 2022 | 27 | $44.1M |
| Q2 2022 | 24 | $63.1M |
| Q1 2022 | 30 | $67.4M |
| Q4 2021 | 32 | $153.5M |
| Q3 2021 | 29 | $150.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Surrozen, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| The Column Group LLC | 616,540 | $9.69M | 6.03% | −11,111−1.8% | Reduced |
| Euclidean Capital LLC | 87,696 | $1.38M | 0.18% | 00.0% | Unchanged |
| Vanguard Group Inc | 61,511 | $966.3K | 0.00% | +29,000+89.2% | Added |
| ArrowMark Colorado Holdings LLC | 55,123 | $831.8K | 0.01% | 00.0% | Unchanged |
| Board of Trustees of The Leland Stanford Junior University | 52,130 | $819.0K | 0.07% | −10.0% | Reduced |
| Morgan Stanley | 35,211 | $553.2K | 0.00% | 00.0% | Unchanged |
| Alyeska Investment Group, L.P. | 20,376 | $320.1K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 13,726 | $216.0K | 0.00% | +3,400+32.9% | Added |
| Geode Capital Management, LLC | 11,473 | $173.2K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 2,412 | $37.9K | 0.00% | −56,082−95.9% | Reduced |
| ADAR1 Capital Management, LLC | 450 | $7.07K | 0.00% | +450 | New |
| Wolverine Asset Management LLC | 281 | $4.41K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 184 | $2.89K | 0.00% | −428−69.9% | Reduced |
| Royal Bank of Canada | 158 | $2.00K | 0.00% | +47+42.3% | Added |
| Wells Fargo & Company | 10 | $157 | 0.00% | +1+11.1% | Added |
| JPMorgan Chase & Co | 3 | $45 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 0 | $0 | 0.00% | −46−100.0% | Sold out |
| Trustees of Columbia University in the City of New York | – | – | – | – | Not filed |